WVE
$10.02
Wave Life Sci Ord Sh
($5.82)
(36.74%)
WVE
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.74)
Revenue:  $16.08 Mil
Monday
Nov 9
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when WVE reports earnings?
Beat
Meet
Miss

Where is WVE's stock price going from here?
Up
Flat
Down
Stock chart of WVE
Analysts
Summary of analysts' recommendations for WVE
Score
Grade
Pivots
Resistance
$12.43
$11.83
$10.93

$10.33

Support
$9.43
$8.83
$7.93
Tweet
Growth
Description
WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.